Last Price$70.5(2.1%)
Market Cap$13.4B
LTM Net Change in Cash
$187.7M
YoY Growth
+513.5%
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
7/10
33.5% overvalued
BioMarin Pharmaceutical Inc. Net Change in Cash
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | $25.0M | $51.1M | $139.2M | ($5,443.0K) | ($55.7M) | ($79.1M) | ($41.8M) | $134.3M | $388.3M | $306.7M | ($478.4M) | $11.3M | $189.7M | ($104.0M) | ($56.5M) | $211.7M | ($61.9M) | $137.3M | $30.6M | $187.7M |
Overvalued or undervalued?
Check the intrinsic value for BMRN
and see if it's the right time to invest.
BioMarin Pharmaceutical Inc. (BMRN) Net Change in Cash comparison analysis
General
LTM Net Change in Cash
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
BioMarin Pharmaceutical Inc.BMRN
$187.7M
513.5%
N/A
N/A
Median Peer Set
($103.6M)
0.0%
0.0%
0.0%
United Therapeutics CorporationUTHR
$489.5M
98.6%
46.4%
47.9%
Royalty Pharma plcRPRX
$452.0M
N/A
(5.3%)
N/A
argenx SEARGX
$327.7M
N/A
11.9%
25.2%
Alnylam Pharmaceuticals, Inc.ALNY
$156.0M
N/A
(21.6%)
4.2%
Summit Therapeutics Inc.SMMT
$33.8M
N/A
84.5%
N/A
Regeneron Pharmaceuticals, Inc.REGN
($241.0M)
(36.8%)
N/A
N/A
BeiGene, Ltd.BGNE
($367.5M)
(67.2%)
66.2%
N/A
Incyte CorporationINCY
($1,524.1M)
N/A
N/A
N/A
BioNTech SEBNTX
($2,059.8M)
(13.9%)
N/A
N/A
Vertex Pharmaceuticals IncorporatedVRTX
($5,800.1M)
4,051.8%
N/A
N/A
BMRN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 25.7 37.7% | 84.2 228.1% | 121.6 44.4% | 296.5 143.9% | 324.7 9.5% | 376.3 15.9% | 441.4 17.3% | 500.7 13.5% | 548.5 9.5% | 751.0 36.9% | 889.9 18.5% | 1,116.9 25.5% | 1,313.6 17.6% | 1,491.2 13.5% | 1,704.0 14.3% | 1,860.5 9.2% | 1,846.3 (0.8%) | 2,096.0 13.5% | 2,419.2 15.4% | 2,853.9 18.0% |
| Cost of Goods Sold (COGS) | 2.6 | 8.7 | 18.4 | 52.5 | 65.9 | 70.3 | 84.0 | 91.8 | 95.7 | 129.8 | 152.0 | 209.6 | 241.8 | 315.3 | 359.5 | 524.3 | 470.5 | 483.7 | 577.1 | 580.2 |
% margin | 23.0 89.8% | 75.5 89.6% | 103.2 84.9% | 244.0 82.3% | 258.7 79.7% | 306.0 81.3% | 357.3 81.0% | 408.9 81.7% | 452.7 82.5% | 621.3 82.7% | 737.9 82.9% | 907.2 81.2% | 1,071.9 81.6% | 1,175.9 78.9% | 1,344.6 78.9% | 1,336.2 71.8% | 1,375.8 74.5% | 1,612.4 76.9% | 1,842.2 76.1% | 2,273.7 79.7% |
| Operating Expenses | 87.3 | 100.1 | 160.5 | 204.2 | 242.3 | 299.0 | 389.8 | 519.1 | 608.8 | 781.7 | 1,019.4 | 1,111.5 | 1,211.6 | 1,349.5 | 1,470.0 | 1,432.4 | 1,458.1 | 1,570.8 | 1,746.3 | 1,789.5 |
| Research & Development Expenses (R&D) | 56.4 | 66.7 | 78.6 | 93.3 | 115.1 | 147.3 | 214.4 | 302.2 | 354.8 | 461.5 | 634.8 | 661.9 | 610.8 | 696.3 | 715.0 | 628.1 | 628.8 | 649.6 | 746.8 | 747.2 |
| Selling, General & Administrative Expenses (SG&A) | 41.6 | 49.0 | 77.5 | 106.6 | 124.3 | 151.7 | 175.4 | 198.2 | 235.4 | 302.2 | 402.3 | 476.6 | 554.3 | 604.4 | 680.9 | 737.7 | 759.4 | 854.0 | 937.3 | 1,009.0 |
% margin | (64.2) (250.2%) | (24.7) (29.3%) | (57.3) (47.1%) | 39.8 13.4% | 16.4 5.1% | 0.5 0.1% | (33.9) (7.7%) | (110.2) (22.0%) | (156.0) (28.4%) | (92.9) (12.4%) | (110.7) (12.4%) | (803.4) (71.9%) | (14.7) (1.1%) | (123.5) (8.3%) | (125.5) (7.4%) | (96.3) (5.2%) | (60.0) (3.3%) | 57.5 2.7% | 194.4 8.0% | 484.2 17.0% |
| Interest Income | 1.9 | 12.9 | 0.0 | 16.4 | 5.1 | 4.1 | 2.9 | 2.6 | 3.1 | 5.9 | 4.5 | 7.5 | 14.9 | 22.8 | 22.7 | 16.6 | 10.5 | 18.0 | 58.3 | 74.9 |
| Interest Expense | 11.9 | 16.7 | 0.0 | 16.4 | 14.1 | 10.3 | 8.3 | 7.6 | 10.4 | 36.6 | 38.2 | 39.5 | 42.7 | 43.7 | 23.5 | 29.3 | 15.3 | 16.0 | 17.3 | 12.3 |
| Pre-tax Income | (74.3) | (28.5) | (15.1) | 33.4 | 0.6 | (21.5) | (43.6) | (118.3) | (176.5) | (124.9) | (154.7) | (831.1) | (35.9) | (142.7) | (94.8) | (42.3) | (75.4) | 149.6 | 188.6 | 541.8 |
% effective tax rate | 21.9 (29.5%) | 23.1 (81.1%) | 0.7 (4.8%) | 2.6 7.8% | 1.1 186.2% | (227.3) 1,057.7% | 10.2 (23.4%) | (3.9) 3.3% | (0.2) 0.1% | 9.1 (7.3%) | 17.1 (11.0%) | (200.8) 24.2% | 81.2 (226.2%) | (65.5) 45.9% | (71.0) 74.8% | (901.4) 2,129.9% | (11.3) 15.0% | 8.0 5.4% | 20.9 11.1% | 114.9 21.2% |
% margin | (74.3) (289.3%) | (28.5) (33.9%) | (15.8) (13.0%) | 30.8 10.4% | (0.5) (0.2%) | 205.8 54.7% | (53.8) (12.2%) | (114.3) (22.8%) | (176.4) (32.2%) | (134.0) (17.8%) | (171.8) (19.3%) | (630.2) (56.4%) | (117.0) (8.9%) | (77.2) (5.2%) | (23.8) (1.4%) | 854.0 45.9% | (64.1) (3.5%) | 141.6 6.8% | 167.6 6.9% | 426.9 15.0% |
| EPS | (1.08) | (0.34) | (0.16) | 0.31 | (0.00) | 1.99 | (0.48) | (0.95) | (1.28) | (0.92) | (1.07) | (3.80) | (0.67) | (0.44) | (0.13) | 4.75 | (0.35) | 0.76 | 0.89 | 2.13 |
| Diluted EPS | (1.08) | (0.34) | (0.16) | 0.29 | (0.00) | 1.73 | (0.48) | (0.95) | (1.28) | (0.92) | (1.07) | (3.79) | (0.67) | (0.44) | (0.13) | 4.53 | (0.35) | 0.75 | 0.87 | 2.06 |
% margin | (54.5) (212.2%) | (14.9) (17.7%) | (57.3) (47.1%) | 67.4 22.7% | 35.6 11.0% | 17.1 4.5% | (0.2) (0.0%) | (79.8) (15.9%) | (137.4) (25.0%) | (50.0) (6.7%) | (110.7) (12.4%) | (705.5) (63.2%) | 94.8 7.2% | (3.5) (0.2%) | 33.9 2.0% | (5.9) (0.3%) | 48.0 2.6% | 267.5 12.8% | 310.3 12.8% | 650.5 22.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is BioMarin Pharmaceutical Inc.'s Net Change in Cash?
As of today, BioMarin Pharmaceutical Inc.'s last 12-month Net Change in Cash is $187.7M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is BioMarin Pharmaceutical Inc.'s Net Change in Cash growth rate?
Over the last year, BioMarin Pharmaceutical Inc.'s Net Change in Cash growth was 513.5%. The average annual Net Change in Cash growth rates for BioMarin Pharmaceutical Inc. have been N/A over the past three years, N/A over the past five years.
3) Is BioMarin Pharmaceutical Inc.'s Net Change in Cash growth rate Good?
Over the last year, BioMarin Pharmaceutical Inc.'s Net Change in Cash growth was 513.5%, which is higher than industry growth of (0.6%). It indicates that BioMarin Pharmaceutical Inc.'s Net Change in Cash growth is Good.